Employees: 48
Size G2GBIO (456160.KS) is a South Korea Health Care company (Biotechnology) with a market value of $416M, the 393rd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩33,600 on 18 Nov 2026.
Performance Over six months the shares fell 52.5%, against -22.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue fell 45.0% over the last twelve months (peer median +4.8%); the operating margin is -2,884.2% (peer median -4.5%).
Valuation It trades at 908.6× enterprise value to sales against a peer median of 4.0× (most expensive of 16).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | ₩423M | ₩769M | ₩740M | ₩241M |
| Revenue growth | — | -45% | +4% | +208% | — |
| Gross profit | n/a | -₩1.49B | -₩1.49B | -₩1.35B | -₩1.38B |
| EBITDA | n/a | -₩10.6B | -₩8.93B | -₩11.4B | -₩9.84B |
| Net income | n/a | -₩12.1B | -₩83.3B | -₩10.5B | ₩15.1B |
| Free cash flow | n/a | -₩14.2B | -₩8.55B | -₩11.8B | -₩14.4B |
| Capital expenditure | n/a | ₩324M | ₩844M | ₩970M | ₩5.68B |
| Total debt | ₩44.0B | ₩7.13B | ₩115B | ₩56.3B | ₩52.8B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 456160.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.2% | -14.1% | 8th highest of 21 |
| 6-month return | -52.5% | -22.0% | 2nd lowest of 21 |
| Distance from 52-week high | -72.9% | -41.5% | 3rd lowest of 21 |
| Revenue growth (TTM) | -45.0% | +4.8% | 2nd lowest of 16 |
| Operating margin | -2,884.2% | -4.5% | lowest of 16 |
| EV / Sales | 908.6× | 4.0× | most expensive of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| G2GBIO 456160.KS | South Korea | $416M | -53% | -45% | -2,884% | 908.6× | n/a | n/a |
| Shanghai Serum Bio-Technology 688163.SS | China | $416M | -34% | -1% | 26% | 10.6× | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $416M | +1% | n/a | n/a | n/a | n/a | n/a |
| Candel Therapeutics CADL | United States | $417M | -31% | n/a | n/a | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $418M | -76% | -65% | -1,112% | 215.1× | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $414M | -5% | +20% | -79% | 10.3× | n/a | n/a |
| Shanghai ZJ Bio-Tech 688317.SS | China | $422M | -22% | -10% | -72% | 2.9× | 4.0% | -62.3% |
| Edding Genor 6998.HK | Hong Kong | $410M | -35% | +1,418% | 26% | 1.0× | -15.3% | +197.3% |
| Hanx Biopharmaceuticals (Wuhan) 3378.HK | Hong Kong | $409M | -24% | n/a | n/a | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $424M | -8% | +44% | -5% | 14.6× | n/a | n/a |
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $427M | +11% | +13% | 47% | 12.3× | 5.3% | +70.5% |
| Qyuns Therapeutics 2509.HK | Hong Kong | $428M | -11% | +230% | 56% | 2.6× | -19.5% | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 1.9× | -18.8% | -36.1% |
| Prothena PRTA | United States | $429M | -11% | +347% | -73% | 3.1× | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | 10.9× | n/a | n/a |
| Scinopharm Taiwan 1789.TW | Taiwan | $435M | -2% | -5% | -4% | 4.0× | 2.1% | +0.5% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | n/a | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $437M | -24% | +5% | 7% | 2.2× | 7.7% | +7.3% |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | 5.2× | n/a | n/a |
| Berry Genomics 000710.SZ | China | $439M | -17% | -2% | -24% | 3.3× | n/a | n/a |
| IRulya Therapeutics IRLA | United States | $440M | +88% | n/a | n/a | n/a | n/a | n/a |